Skip to main content
TanyaKanker

Decision tool

Biomarker explorer

Explore biomarkers by name, cancer type, and whether related medicines are recorded. Open a result to see its meaning, limits, related tests, treatment categories, and studies requiring that marker.

What you get

Understand what a biomarker result means and what it does not establish.

Open each result for its meaning, limits, related tests, and related studies.

Unggah Laporan MedisSee other tools

One biomarker result is not a treatment decision

Doctors interpret biomarker results together with pathology, imaging, and the clinical context. This tool helps you find the right pages and questions; it does not interpret your test result.
Marker name, alias, or a term from the report.

25 biomarkers match these filters

  • EGFR

    Also written as: EGFR sensitizing mutation, EGFR exon 19 deletion, EGFR L858R, EGFR exon 20 insertion

    Changes in the EGFR gene can make lung cancer cells grow more aggressively; the result affects which targeted therapy categories are worth discussing.

    5 related medicines4 tests11 related studies

  • ALK

    Also written as: ALK fusion, ALK rearrangement, EML4-ALK

    ALK gene fusion is one of the most important markers to discuss in advanced non-small-cell lung cancer.

    5 related medicines4 tests0 related studies

  • ROS1

    Also written as: ROS1 fusion, ROS1 rearrangement

    ROS1 fusion is a rare marker that can direct discussion toward specific targeted therapy categories.

    4 related medicines4 tests2 related studies

  • KRAS

    Also written as: KRAS G12C, KRAS G12D, KRAS mutation

    Some specific KRAS changes in lung cancer can now be targeted, while others remain limited to standard pathways or clinical trials.

    3 related medicines3 tests15 related studies

  • MET

    Also written as: MET exon 14 skipping, MET amplification, MET exon 14

    MET changes can be exon 14 skipping or amplification; the two are discussed differently in treatment planning.

    4 related medicines3 tests3 related studies

  • RET

    Also written as: RET fusion, RET rearrangement

    RET fusion is rare, but when found it can open discussion of a specific targeted therapy category.

    2 related medicines3 tests1 related studies

  • BRAF

    Also written as: BRAF V600E, BRAF mutation

    BRAF V600E mutation can be discussed in the category of combination targeted therapy for some patients.

    3 related medicines4 tests3 related studies

  • HER2

    Also written as: ERBB2, HER2 overexpression, HER2 amplification, HER2-low

    HER2 status is assessed on tissue testing; the result affects treatment categories in stomach cancer and some lung cancers.

    3 related medicines4 tests12 related studies

  • NTRK

    Also written as: NTRK fusion, TRK fusion, NTRK1, NTRK2, NTRK3

    NTRK fusion is very rare, but is a marker that can be discussed across cancer types.

    3 related medicines3 tests1 related studies

  • PD-L1

    Also written as: TPS, CPS, PD-L1 expression

    PD-L1 is a protein marker assessed with a score; the score helps interpret the relevance of immunotherapy categories.

    5 related medicines2 tests5 related studies

  • MSI / MMR

    Also written as: MSI-high, dMMR, mismatch repair, instabilitas mikrosatelit

    MSI/MMR status reflects DNA repair function in the tumour and can open an immunotherapy category.

    4 related medicines4 tests1 related studies

  • CLDN18.2

    Also written as: Claudin 18.2, CLDN18.2 positivity

    CLDN18.2 is a cell-surface protein that can be a marker for a targeted therapy category in stomach cancer.

    1 related medicines2 tests1 related studies

  • CD19

    Also written as: CD19 positive, CD19 expression

    CD19 is a marker on B cells and is the basis for several cellular therapies, including some CAR-T categories.

    4 related medicines3 tests7 related studies

  • CD20

    Also written as: CD20 positive

    CD20 is a classic marker in B-cell lymphoma and is the basis for a major antibody therapy group.

    5 related medicines3 tests1 related studies

  • CD30

    Also written as: CD30 positive

    CD30 is an important marker in Hodgkin lymphoma and some T-cell lymphomas.

    1 related medicines2 tests0 related studies

  • Del(17p) / TP53

    Also written as: del(17p), TP53 mutation, high risk cytogenetics

    17p deletion and TP53 mutation are high-risk cytogenetic factors in multiple myeloma.

    5 related medicines3 tests0 related studies

  • TMB (tumour mutational burden)

    Also written as: tumor mutational burden, beban mutasi tumor

    TMB measures how many changes are present in tumour DNA and is sometimes used as an additional consideration in immunotherapy discussion.

    2 related medicines1 tests0 related studies

  • BCMA

    Also written as: B-cell maturation antigen, TNFRSF17

    BCMA is a marker on plasma cells and is the basis for several advanced therapies in multiple myeloma.

    4 related medicines3 tests0 related studies

  • GPRC5D

    Also written as: G protein-coupled receptor class C group 5 member D

    GPRC5D is an alternative marker on myeloma cells used when BCMA targeting is no longer effective.

    1 related medicines2 tests0 related studies

  • CD22

    Also written as: CD22 antigen

    CD22 is a marker on B cells used as a target in some leukemias and B-cell lymphomas.

    1 related medicines2 tests0 related studies

  • GPC3

    Also written as: glypican-3

    GPC3 is a surface protein often found in hepatocellular carcinoma and is being studied as a therapy target.

    0 related medicines2 tests0 related studies

  • BRCA1 / BRCA2

    Also written as: BRCA1, BRCA2, germline BRCA, somatic BRCA

    BRCA1 or BRCA2 changes can be inherited or limited to the tumour, and affect treatment discussion as well as family risk.

    1 related medicines2 tests0 related studies

  • MGMT

    Also written as: MGMT promoter methylation, metilasi promotor MGMT

    MGMT promoter methylation status is discussed in glioma and relates to how cells repair damage caused by certain drugs.

    1 related medicines2 tests0 related studies

  • FLT3

    Also written as: FLT3-ITD, FLT3-TKD, FLT3 mutation

    Changes in the FLT3 gene are findings often discussed in acute myeloid leukemia.

    2 related medicines2 tests0 related studies

  • BCR-ABL

    Also written as: Philadelphia chromosome, kromosom Philadelphia, BCR-ABL1

    The BCR-ABL transcript is a defining marker in chronic myeloid leukemia and some acute lymphoblastic leukemia.

    3 related medicines3 tests0 related studies

Suggested sequence

  1. 1. Read what your biomarker result means and confirm that the test appears in the report.
  2. 2. Review the tests and treatment categories that depend on that biomarker.
  3. 3. Check studies requiring the biomarker and keep each study status distinct.
  4. 4. Prepare a report summary so molecular results stay together with the diagnosis and treatment history.

Not a diagnosis and not final medical advice. Must be reviewed by a doctor.